title: Neointimal response to second-generation drug-eluting stents in diabetic patients with de-novo coronary lesions: intravascular ultrasound study.
abstract: OBJECTIVE
  The aim of this study was to evaluate the extent of neointimal response after the implantation of a second-generation drug-eluting stent, zotarolimus-eluting stent (ZES-ER, Endeavor Resolute) or everolimus-eluting stent (EES, Xience V), using intravascular ultrasound (IVUS) in diabetic patients.
  
  
  METHODS
  In all, 154 diabetic patients with de-novo coronary lesions were randomized to be implanted with a ZES-ER or EES, and the angiographic follow-up at 9 months combined with a complete IVUS study was available for 96 patients with 101 lesions.
  
  
  RESULTS
  Baseline demographic and lesion parameters were similar in both groups at index percutaneous coronary intervention. On follow-up angiography, in-stent late lumen loss and minimal lumen diameter were not different between the two groups. On IVUS study, neointimal hyperplasia volume [median (interquartile range): ZES-ER vs. EES; 2.25 mm (0.57-6.25) vs. 1.59 mm (0.45-8.37), P=0.615] and in-stent percentage of volume obstruction [median (interquartile range): ZES-ER vs. EES; 1.16% (0.33-3.61) vs. 0.77% (0.29-4.01), P=0.615] showed similar results between the two groups.
  
  
  CONCLUSIONS
  In diabetic patients, the second-generation drug-eluting stents, ZES-ER and EES, were comparable in inhibiting neointimal proliferation.
authors.affiliation: aDivision of Cardiology, Gangnam Severance Hospital bDivision of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine cDepartment of Internal Medicine, Division of Cardiology, College of Medicine, Chung-Ang University dCardiology Department, Eulji General Hospital, Eulji University, Seoul eDepartment of Cardiology, Dankook University Hospital, Cheonan fDepartment of Cardiology, Wonju Severance Christian Hospital, Wonju College of Medicine, Yonsei University, Wonju gDivision of Cardiology, National Health Insurance Corporation Ilsan Hospital, Goyang, Republic of Korea.
authors.forename: Hoyoun
authors.initials: H
authors.lastname: Won
authors.forename: Tae Soo
authors.initials: TS
authors.lastname: Kang
authors.forename: Bum-Kee
authors.initials: BK
authors.lastname: Hong
authors.forename: Seunghwan
authors.initials: S
authors.lastname: Lee
authors.forename: Dong Woon
authors.initials: DW
authors.lastname: Jeon
authors.forename: Sung Kee
authors.initials: SK
authors.lastname: Ryu
authors.forename: Pil-Ki
authors.initials: PK
authors.lastname: Min
authors.forename: Young Won
authors.initials: YW
authors.lastname: Yoon
authors.forename: Byoung Kwon
authors.initials: BK
authors.lastname: Lee
authors.forename: Hyuck Moon
authors.initials: HM
authors.lastname: Kwon
authors.forename: Young-Guk
authors.initials: YG
authors.lastname: Ko
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058426:Neointima; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D056910:Republic of Korea; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus